M35.3

Polymyalgia rheumatica

Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disorder predominantly affecting individuals over the age of 50. It is characterized by severe aching and morning stiffness, primarily located in the proximal joints including the shoulders, pelvic girdle, and neck. The clinical hallmark of PMR is its rapid and dramatic response to low-dose systemic corticosteroids. While the exact etiology remains idiopathic, it is known to be closely associated with giant cell arteritis (GCA), a form of vasculitis that occurs in approximately 15-20% of patients with PMR. Pathologically, the condition involves subdeltoid bursitis, trochanteric bursitis, and tenosynovitis, rather than primary muscle inflammation. Diagnostic evaluation typically reveals elevated inflammatory markers such as Erythrocyte Sedimentation Rate (ESR) and C-reactive protein (CRP).

Clinical Symptoms

Bilateral shoulder aching and stiffness
Pelvic girdle pain and stiffness
Morning stiffness lasting more than 45 minutes
Difficulty rising from a seated position
Difficulty raising arms above shoulder height
Low-grade fever
Unintentional weight loss
Generalized malaise and fatigue
Depression or irritability
Peripheral joint swelling (less common)
Carpal tunnel syndrome (rarely associated)

Common Causes

Idiopathic (primary cause unknown)
Genetic predisposition associated with HLA-DR4 alleles
Immunosenescence (age-related immune system changes)
Environmental triggers such as seasonal viral infections
Autoimmune-mediated inflammation of synovial and bursal structures

Documentation & Coding Tips

Distinguish between isolated PMR and PMR associated with Giant Cell Arteritis (GCA).

Example: Patient presents with proximal muscle stiffness in shoulders and pelvic girdle lasting 60 minutes each morning. ESR is 55 mm/hr. There are no signs of temporal headache, jaw claudication, or visual changes. Diagnosis is Polymyalgia Rheumatica (M35.3). Plan includes Prednisone 15mg daily with a slow taper. If GCA was suspected, M31.5 would be the primary code, significantly impacting the risk adjustment and hierarchical condition category (HCC) weight.

Billing Focus: Identify the absence of vasculitis to ensure M35.3 is the primary code and not a manifestation of M31.5.

Explicitly document the duration and location of morning stiffness.

Example: A 68-year-old female reports severe bilateral shoulder and hip stiffness persisting for 90 minutes after waking. Symptoms have been present for 3 weeks. Laboratory findings show CRP 12.4 mg/L. Physical exam shows limited active ROM in shoulders bilaterally but no synovitis of small joints. This documentation supports the clinical criteria for M35.3 and justifies moderate complexity MDM.

Billing Focus: Laterality and specific anatomical sites (shoulders/hips) support the clinical necessity for imaging or therapeutic injections if performed.

Record the clinical response to low-dose corticosteroids as diagnostic evidence.

Example: Follow-up for PMR (M35.3). Patient reports 80 percent improvement in proximal stiffness within 48 hours of initiating Prednisone 15mg. Repeat ESR has decreased from 65 to 22 mm/hr. Continuing taper protocol. This dramatic response confirms the diagnosis and supports the continued use of long-term steroid therapy, which carries its own risk profile.

Billing Focus: Documentation of steroid response justifies the continued medical management (99214) and the need for monitoring for adverse effects.

Specify the exclusion of other systemic inflammatory or neoplastic processes.

Example: Patient with bilateral shoulder pain and elevated ESR. Negative RF and anti-CCP antibodies rule out Rheumatoid Arthritis. No weight loss or night sweats to suggest occult malignancy. Normal TSH rules out hypothyroid-induced myalgias. Clinical picture is consistent with Polymyalgia Rheumatica (M35.3).

Billing Focus: Documentation of differential diagnosis logic supports a higher level of Medical Decision Making (MDM) due to the complexity of ruling out mimics.

Document monitoring for steroid-sparing agents in refractory cases.

Example: PMR (M35.3) remains active despite Prednisone 10mg daily; patient experiences flare with any attempt to taper lower. Initiating Methotrexate 15mg weekly as a steroid-sparing agent. Monitoring CBC and CMP for drug toxicity. This level of management indicates high-risk medication monitoring.

Billing Focus: Justifies CPT 99214 or 99215 based on the high risk of morbidity from both the disease and the treatment (Methotrexate).

Relevant CPT Codes

99214 - Office visit established patient moderate complexity
Most common for PMR follow-up involving steroid titration and monitoring for adverse effects of chronic therapy.
99204 - Office visit new patient moderate complexity
Standard for initial diagnosis of PMR where multiple differentials must be excluded.
85652 - Sedimentation rate erythrocyte automated
Primary laboratory marker for diagnosing and monitoring PMR activity.
86140 - C-reactive protein
Used in conjunction with ESR to assess inflammatory status.
76881 - Ultrasound extremity non-vascular real-time with image documentation complete
Used to detect subdeltoid bursitis or trochanteric bursitis, which supports the PMR diagnosis.
99213 - Office visit established patient low complexity
Used for stable patients on a maintenance dose with no new symptoms or complications.
85025 - Blood count complete CBC automated and automated differential WBC count
Monitors for anemia of chronic disease and steroid-induced leukocytosis.
86200 - Cyclic citrullinated peptide CCP antibody
Crucial for distinguishing PMR from seropositive rheumatoid arthritis.
96372 - Therapeutic prophylactic or diagnostic injection subcutaneous or intramuscular
Sometimes used for initial high-dose steroid bolus or biologic administration (e.g., Sarilumab).
99215 - Office visit established patient high complexity
Appropriate for patients with severe flares, significant steroid complications, or multi-organ involvement.